Claims for Patent: 9,181,524

Summary for Patent: 9,181,524

Title:	Modalities for the treatment of degenerative diseases of the retina
Abstract:	This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
Inventor(s):	Klimanskaya; Irina V. (Upton, MA), Lanza; Robert P. (Clinton, MA)
Assignee:	Ocata Therapeutics, Inc. (Marlborough, MA)
Application Number:	14/227,237
Patent Claims:	1. A method for the differentiation of human embryonic stem (hES) cells, said method comprising: a) culturing an embryoid body (EB), produced from hES cells, for a sufficient time for the appearance of pigmented cells comprising brown pigment dispersed in their cytoplasm, under conditions that do not maintain stem cells in an undifferentiated state, wherein the hES cells are stem cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60 and TRA-I-81; and b) isolating and culturing the pigmented cells under adherent conditions to form a population of cells that expresses bestrophin, CRALBP, PEDF1 and RPE65. 2. The method of claim 1, further comprising repassaging the population of cells of (b) one or more times. 3. The method of claim 1, wherein the population of cells in (b) comprises cells having a cobblestone, polygonal appearance. 4. The method of claim 3, wherein the population of cells in (b) comprises cells that are tightly packed. 5. The method of claim 1, further comprising isolating the population of cells in (b) as a suspension. 6. The method of claim 1, further comprising isolating the population of cells in (b) as a monolayer. 7. The method of claim 1, further comprising isolating and placing the population of cells in (b) on a matrix or a substrate. 8. The method of claim 1, wherein step (a) comprises culturing the EB in the absence of feeder cells. 9. The method of claim 1, wherein the EB is produced by culturing hES cells under low adherent conditions. 10. The method of claim 1, wherein the EB is produced by culturing hES cells on low adherent plates. 11. The method of claim 1, wherein isolating the pigmented cells comprises contacting the pigmented cells with one or more enzymes selected from the group consisting of trypsin, collagenase and dispase. 12. The method of claim 1, further comprising isolating and transplanting the population of cells into an eye of a patient to treat a retinal disease or condition. 13. The method of claim 12, wherein the population of cells is transplanted by vitrectomy surgery into the subretinal space of the eye of the patient. 14. The method of claim 12, wherein the patient has a retinal disease or condition selected from the group consisting of retinitis pigmentosa, retinal detachment, retinal dysplasia, retinal atrophy, retinopathy, macular dystrophy, cone dystrophy, cone-rod dystrophy, Malattia Leventinese, Doyne honeycomb dystrophy, Sorsby's dystrophy, pattern/butterfly dystrophies, Best vitelliform dystrophy, North Carolina dystrophy, central areolar choroidal dystrophy, angioid streaks, or a toxic maculopathy. 15. The method of claim 12, wherein the patient has Stargardt disease, pathologic myopia, retinitis pigmentosa, or macular degeneration. 16. The method of claim 12, wherein the patient has age-related macular degeneration. 17. The method of claim 12, wherein the population of cells is cryopreserved and then thawed prior to being transplanted into the patient. 18. The method of claim 12, wherein the population of cells is in a suspension. 19. The method of claim 12, wherein the population of cells is a monolayer. 20. The method of claim 12, wherein the population of cells is on a matrix or a substrate.

Details for Patent 9,181,524

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2024-01-23